|
17 Jan 2019 |
Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019
|
|
12 Jan 2019 |
Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
|
|
10 Jan 2019 |
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
|
|
07 Jan 2019 |
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
|
|
03 Jan 2019 |
First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors
|
|
27 Dec 2018 |
Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
|
|
22 Dec 2018 |
FDA approves longer-acting calaspargase pegol-mknl for ALL
|
|
20 Dec 2018 |
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
|
|
20 Dec 2018 |
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
|
|
20 Dec 2018 |
Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes
|
|
19 Dec 2018 |
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
|
|
19 Dec 2018 |
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial Dec
|
|
17 Dec 2018 |
Cerenis Therapeutics: Final Results of TARGET PHASE II Study Demonstrate the Ability of CER-001, an HDL Mimetic, to Target Tumor in Patients with Esophageal Cancer
|
|
14 Dec 2018 |
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
|
|
14 Dec 2018 |
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
|
|
12 Dec 2018 |
Levo Therapeutics Announces Initiation of the CARE-PWS Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
|
|
11 Dec 2018 |
Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
|
|
11 Dec 2018 |
Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes That CollPlant's Vergenix™ STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow
|
|
09 Dec 2018 |
Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
|
|
05 Dec 2018 |
CERENIS Announces the Results of TANGO, a Phase III Clinical Study Evaluating CER-001 in Patients with HDL Deficiency
|
|
04 Dec 2018 |
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
|
|
04 Dec 2018 |
Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
|
|
03 Dec 2018 |
Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
|
|
29 Nov 2018 |
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
|
|
28 Nov 2018 |
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
|
